Pegcetacoplan Long Term Safety and Efficacy Extension Study
Condition: PNH · Sponsor: Apellis Pharmaceuticals, Inc.
About this study
This is an Open-label, Non-Randomized, Multi-Center Extension Study. Eligible subjects will have previously completed a pegcetacoplan study.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (62)
| University of Southern California | Los Angeles, California, United States | — |
| Denver Health Medical Center | Denver, Colorado, United States | — |
| Cancer Specialists of North Florida | Jacksonville, Florida, United States | — |
| Lakes Research | Miami, Florida, United States | — |
| Northwestern University | Chicago, Illinois, United States | — |
| Investigative Clinical Research of Indiana | Indianapolis, Indiana, United States | — |
| Duke University Medical Center | Durham, North Carolina, United States | — |
| Cleveland Clinic | Cleveland, Ohio, United States | — |
| Baptist Cancer Center | Memphis, Tennessee, United States | — |
| Royal Melbourne Hospital | Melbourne, Victoria, Australia | — |
| Cliniques Universitaires Saint-luc | Brussels, Belgium | — |
| AZ Delta | Roeselare, Belgium | — |
+ 50 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03531255